HI-GREAT GROUP HOLDING COMPANY Hi-Great Group Holding Company Share Price
Equities
HIGR
US4283711087
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0178 USD | -98.22% |
|
-.--% | -.--% |
| Sales 2021 | 0.26 22.04 | Sales 2022 | 0.21 17.34 | Capitalization | 1.78M 148M |
|---|---|---|---|---|---|
| Net income 2021 | - 0 | Net income 2022 | - 0 | EV / Sales 2021 | 37,85,16,662 x |
| Net Debt 2021 | 1.83K 153K | Net Debt 2022 | 26.42K 2.2M | EV / Sales 2022 | 86,90,826 x |
| P/E ratio 2021 |
1,623
x | P/E ratio 2022 |
539
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 17.06% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -98.22% |
3 years
0.02
1.00
5 years
0.006.00
10 years
0.006.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ho Yang Jun
CEO | Chief Executive Officer | 59 | 25/20/25 |
Soon Yang Ho
DFI | Director of Finance/CFO | 53 | 14/19/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ho Yang Jun
CEO | Chief Executive Officer | 59 | 25/20/25 |
Soon Yang Ho
DFI | Director of Finance/CFO | 53 | 14/19/14 |
Hi-Great Group Holding Company holds a license agreement for New Business Plan with the KRAS gene, which is among the most frequently mutated genes across all cancers, including pancreatic, lung, and colorectal. The Company is engaged in marketing, selling, and distributing SellaCare, Inc's organic longevity health supplement. The Company is in license agreement with SellaCare, Inc. in the areas of longevity and additional health benefits and it also expands into the cosmetic sector as an overall sustainable revenue platform.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 1.78M | |
| +1.51% | 42.75B | |
| +48.37% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- HIGR Stock
